Dr Dongbin Jin
Dongbin completed his Bachelor of Science majoring in Biochemical Engineering and Master of Science majoring in Life Science, before completing his PhD at the Garvan Institute under the supervision of Prof Jonathan Sprent.
During his PhD research, Dongbin developed a fundamentally new form of therapeutic cancer vaccine that was able to eradicate established tumours in animal studies.
He is currently extending these novel findings into more clinically relevant settings.
2007 – MSc, POSTECH – South Korea
2003 – BSc, YUST – China
Kim KS, Jin DB, Ahn SS, Park KS, Seo SH, Suh YS, Sung YC. (2010). HIV-1 protease has a genetic T-cell adjuvant effect which is negatively regulated by proteolytic activity. Journal of Virology 84(15), 7743-9